Maravai Lifesciences Holdings, Inc. MRVI
We take great care to ensure that the data presented and summarized in this overview for MARAVAI LIFESCIENCES HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRVI
View all-
Gtcr LLC20.2MShares$50.6 Million4.99% of portfolio
-
12 West Capital Management LP New York, NY12.5MShares$31.4 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$29.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.73MShares$24.4 Million0.0% of portfolio
-
Braidwell LP Stamford, CT8.35MShares$21 Million1.13% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A66.11MShares$15.3 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.11MShares$10.3 Million0.01% of portfolio
-
Mirabella Financial Services LLP London, X03.74MShares$9.39 Million0.35% of portfolio
-
State Street Corp Boston, MA2.73MShares$6.84 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.66MShares$6.69 Million0.0% of portfolio
Latest Institutional Activity in MRVI
Top Purchases
Top Sells
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Insider Transactions at MRVI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 30
2025
|
Rajesh Asarpota Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+50.0%
|
-
|
Jun 16
2025
|
Murali Prahalad Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+36.57%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+38.19%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Luke Joseph Marker Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+39.23%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Susannah Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+34.41%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Benjamin James Daverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+39.23%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
John A De Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+35.9%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Jessica Hopfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+30.84%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
Constantine S Mihas Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+39.23%
|
$178,278
$2.16 P/Share
|
Jun 16
2025
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
231,481
+38.75%
|
$462,962
$2.16 P/Share
|
Jun 16
2025
|
Sean Laurence Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,139
+39.23%
|
$178,278
$2.16 P/Share
|
Jun 08
2025
|
Bernd Brust Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000,000
+50.0%
|
-
|
May 15
2025
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,381
+0.5%
|
$2,381
$1.67 P/Share
|
May 15
2025
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
876
+0.13%
|
$876
$1.67 P/Share
|
Mar 17
2025
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
246,549
+34.35%
|
-
|
Mar 17
2025
|
William E. Martin Iii Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
986,194
+35.21%
|
-
|
Mar 17
2025
|
Peter Michael Leddy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
394,478
+35.01%
|
-
|
Mar 17
2025
|
Rebecca Buzzeo Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,858
+32.78%
|
-
|
Mar 17
2025
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
295,858
+39.3%
|
-
|
Mar 17
2025
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
394,478
+36.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 6.29M shares |
---|---|
Bona fide gift | 20.6K shares |
Open market or private purchase | 193K shares |
Payment of exercise price or tax liability | 494K shares |
---|---|
Bona fide gift | 20.6K shares |
Open market or private sale | 25K shares |